Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Calyxt, Inc. (Nasdaq: CLXT) has successfully completed a 1-for-10 reverse stock split of its common stock, effective April 24, 2023. This decision was approved by shareholders on June 1, 2022, and aims to enhance the company's stock price and maintain compliance with Nasdaq listing standards. Post-split, the number of outstanding shares has decreased from approximately 49.7 million to about 5 million, but the total authorized shares remain unchanged. The stock will resume trading on an adjusted basis on April 25, 2023, under the symbol CLXT and a new CUSIP number. The company’s equity-based awards will be adjusted proportionately. No action is required from registered stockholders as their holdings will be automatically updated.
Cellectis has announced the implementation of alemtuzumab as an Investigational Medicinal Product (IMP), coded CLLS52, in its clinical trials for UCART22, UCART123, and UCART20x22. This addition to the lymphodepletion regimen has shown prolonged lymphodepletion and increased cell expansion leading to greater clinical activity. The trials focus on patients with relapsed/refractory B-cell ALL, AML, and NHL. This collaboration with Sanofi, which began in May 2021, involves the supply of alemtuzumab for these studies. The findings from the BALLI-01 and AMELI-01 studies are promising, indicating a significant step forward for Cellectis' allogeneic CAR T-cell therapies, enhancing their therapeutic potential against various cancers.
Cellectis, a clinical-stage biotechnology company specializing in gene-editing, recently presented preclinical data on TALEN®-edited MUC1 CAR T-cells at the AACR Annual Meeting 2023. This research highlights the potential of these CAR T-cells to effectively target relapsed and refractory triple-negative breast cancer (TNBC), a condition with limited treatment options. MUC1, a tumor-associated antigen overexpressed in many TNBC patients, serves as a precise target for the therapy. The preclinical results indicate that the armored MUC1 CAR T-cells could not only control tumor growth but also aid in the recovery of normal tissues. Cellectis aims to leverage the unique properties of MUC1 for innovative and safe CAR T-cell therapies.
Cellectis, a clinical-stage biotechnology company, announced key information regarding its share structure as of March 31, 2023. The total number of shares in capital stands at 55,583,768, while the total number of voting rights is 61,504,923. Cellectis focuses on innovative gene editing technologies, specifically TALEN and PulseAgile, to develop advanced cell and gene therapies aimed at treating cancers such as acute myeloid leukemia and multiple myeloma. The company operates under two primary platforms: UCART for CAR-T immunotherapies and .HEAL for hemopoietic stem cell therapies. Cellectis is listed on Nasdaq (CLLS) and Euronext Growth (ALCLS), with headquarters in Paris and additional locations in New York and Raleigh.
Cellectis, a leading clinical-stage biotechnology company, announced significant progress in its BALLI-01 clinical study evaluating UCART22, the most advanced allogeneic CAR T-cell product for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The first patient in Europe has been dosed in France after completing the 28-day Dose Limiting Toxicity period. This milestone underscores Cellectis' commitment to developing off-the-shelf therapies for patients who have not responded to other treatments. UCART22 targets the CD22 antigen, aiming to provide new therapeutic options. With proprietary GMP manufacturing facilities in Raleigh and Paris, Cellectis maintains control over production timelines, enhancing patient treatment prospects. Positive preliminary clinical data was shared in December 2022, supporting the continued administration of UCART22 post FCA lymphodepletion.